Drugs / CD-801
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06418659 | Oct 2024 → Apr 2026 overdue | hepatocellular carcinoma | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06572189 | Aug 2024 → Jul 2026 | intrahepatic cholangiocarcinoma | Shanghai Changzheng Hospital | Withdrawn | No outcome recorded |
| Phase 0 | NCT06092112 | Oct 2023 → Apr 2024 | hepatocellular carcinoma | Shanghai Changzheng Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06572189 ↗ |
| Route | Intravenous | “CD-801 will be administered intravenously for the treatment of HCC.” NCT06418659 ↗ |
| Target | HNF4A | “a drug designed specifically to enhance the expression of HNF4α and selectively target liver cancer cells” NCT06092112 ↗ |